191 related articles for article (PubMed ID: 35379454)
1. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.
Ulaner GA
Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
[TBL] [Abstract][Full Text] [Related]
2. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
3. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
4. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-
Ulaner GA; Mankoff DA; Clark AS; Fowler AM; Linden HM; Peterson LM; Dehdashti F; Kurland BF; Mortimer J; Mouabbi J; Moon DH; de Vries EGE
J Nucl Med; 2023 Mar; 64(3):351-354. PubMed ID: 36863779
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
6. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
Katzenellenbogen JA
Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
[TBL] [Abstract][Full Text] [Related]
7. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
10. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
12. Clinical Validity of 16α-[
van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
[TBL] [Abstract][Full Text] [Related]
13. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
[TBL] [Abstract][Full Text] [Related]
14. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
16. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract][Full Text] [Related]
19. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
20. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]